{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 120,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide uses a combination of microscopy images and a line chart to demonstrate efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/31",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 1,
        "x": 0,
        "y": 0.85
      },
      "kind": "callout",
      "text": "saRNA showed potential as a vaccine modality with much lower doses. Comparable immunogenicity with approximately 100-fold lower doses of saRNA compared to mRNA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "733a2bc9-66ff-4639-879d-073c4ded6e70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.51,
        "y": 0.235
      },
      "kind": "chart",
      "text": "In vivo expression over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c715e691-7a56-4527-8047-41fd62ae7225",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.05,
        "y": 0.235
      },
      "kind": "image",
      "text": "In vitro expression microscopy images",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01d5a9a2-2452-45e2-b1a9-ca12f1fd2e8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "mRNA technology | saRNA could induce higher and extended in vitro and in vivo expression compared to mRNA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "052af325-a11d-4555-9ffb-9b00fb432392",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6e469762-2fe1-4368-99f0-2abcf2c03c78",
      "evidence": "callout/primary: saRNA showed potential as a vaccine modality with much lower doses. Comparable immunogenicity with approximately 100-fold lower doses of saRNA compared to mRNA",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "1643fbe3-1fb1-42e5-8f44-f19ba326ced7",
      "evidence": "Compares mRNA vs saRNA performance metrics",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}